Aura Biosciences is a biotechnology company focused on developing a new class of therapies designed to target and selectively destroy tumor cells. The company's lead program, AU-011, is aimed at treating ocular melanoma, a rare and aggressive eye cancer. This program has been developed in collaboration with the National Cancer Institute (NCI) and has received orphan drug status from the US Food and Drug Administration (FDA).

Aura Biosciences operates in the oncology market, specifically targeting cancers that are difficult to treat with conventional methods. The company's innovative approach involves light-activated therapies that can precisely target solid tumors and metastases without damaging surrounding healthy tissue. This precision reduces the invasiveness and toxicity typically associated with cancer treatments.

The business model of Aura Biosciences involves the development and commercialization of its proprietary therapies. The company generates revenue through the sale of its therapeutic products, once they receive regulatory approval, and potentially through partnerships and licensing agreements with other pharmaceutical companies.

Aura Biosciences serves patients suffering from ocular melanoma and potentially other cancers in the future as its technology platform expands. The company is committed to advancing its clinical trials and bringing its innovative treatments to market to improve patient outcomes.

Keywords: biotechnology, ocular melanoma, tumor targeting, light-activated therapy, orphan drug, National Cancer Institute, FDA approval, oncology, precision medicine, clinical trials.